Real-world antibiotic use in treating acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in China: Evidence from the ACURE study

Background: The evidence for real-world antibiotic use in treating acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is insufficient. This study aimed to investigate the management AECOPD China. Methods: All hospitalized patients from exacerbation inpatient registry (ACURE) conducted at 163 sites between January 2018 and December 2019 were screened according eligible criteria. population was divided into secondary tertiary hospital groups. Patients’ baseline characteristics, use, bacterial pathogen characteristics retrieved analyzed using SPSS 23.0. Results: A total 1663 included study, including 194 hospitals 1469 hospitals. Among enrolled, 1434 (86.2%) received treatment, comprising approximately 85.6% 86.3% groups, respectively. median therapy duration 9.0 (interquartile range [IQR]: 7.0 - 11.0)°days. Regarding routes 1400 (97.6%) intravenous antibiotics, 18 (1.3%) oral 15 (1.0%) both one (0.1%) patient nebulized treatment. In addition, cephalosporin, penicillin, quinolone most commonly prescribed antibiotics (43.6%, 37.0%, 34.2%, respectively). total, 990 (56.5%) underwent examinations; proportion receiving examinations second group significantly lower than that (46.4% vs 61.3%, p < 0.001). Conclusion: demonstrates an overuse may exist treatment Measures should be taken prevent potential antimicrobial resistance (AMR) Chinese patients.